Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Cisplatin for the Treatment of Recurrent Mucinous Ovarian Cancer, HI-MOC Study

Inclusion Criteria

• Patients must have histologically or cytologically confirmed recurrent primary mucinous ovarian cancer or suspicion of recurrence based on imaging in those with previous history of primary mucinous ovarian cancer or borderline mucinous neoplasm
• Age >= 18 years
• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
• Absolute neutrophil count > 1,500/mcL (within 30 days of registration)
• Platelets > 100,000/mcL (within 30 days of registration)
• Total bilirubin =< 1.5 mg/dL (within 30 days of registration)
• Creatinine =< 1.5 mg/dL (within 30 days of registration)
• Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3 X institutional upper limit of normal (within 30 days of registration)
• Patients must be > 2 weeks from prior chemotherapy or radiation therapy, except for bevacizumab treatment which requires > 6 weeks
• Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria

• Patients who are receiving concurrent investigational therapy or who have received investigational therapy within 30 days of HIPEC (investigational therapy is defined as treatment for which there is currently no regulatory authority approved indication)
• Patients with known active central nervous system (CNS) metastases
• Patients with known hypersensitivity to any of the components of cisplatin
• Patients with a prior or concurrent malignancy who natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
• Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Women who are pregnant or nursing women
• Patients with peripheral neuropathy >= grade 2
• History of allogenic transplant
• History of prior HIPEC or intraperitoneal chemotherapy
• Known bulky extra-abdominopelvic disease
• Patients with hearing impairment/tinnitus >= grade 2
• Patients with medical, psychiatric, cognitive or other conditions that compromise the patient's ability to understand the patient information, to give informed consent, to comply with the study protocol or to complete the study